
via National Institute on Aging
NIH-funded study identifies gene variant as potential drug target
Defying the odds, an individual at high risk for early-onset Alzheimer’s disease remained dementia-free for many years beyond what was anticipated. A study funded in part by the National Institute on Aging (NIA), part of the National Institutes of Health, led researchers to suggest that a gene variant may be the key, perhaps providing a new direction toward developing a treatment.
The research focused on the case of a woman who carried a gene mutation known to cause early-onset Alzheimer’s. However, she did not develop signs of the disease until her seventies, nearly three decades after her expected age of onset. The researchers suspect that she may have been protected because in addition to the gene mutation causing early-onset Alzheimer’s in her family, she also had two copies of the APOE3 Christchurch (APOE3ch) gene variant. Findings of this case study as published in Nature Medicine suggest that two copies of the APOE3ch variant, named after Christchurch, New Zealand where it was first identified, may protect against Alzheimer’s.

“Sometimes close analysis of a single case can lead to discovery that could have broad implications for the field,” said NIA Director Richard J. Hodes, M.D. “We are encouraged that as part of our wide array of studies, this research in the unique genetic makeup of an exceptional individual can reveal helpful information.”
Early-onset Alzheimer’s disease is rare, representing less than 10% of all people who have Alzheimer’s. It typically occurs between a person’s 30s to mid-60s. Risk for both early- and late-onset Alzheimer’s disease is affected by genetic factors.
For the study, researchers led by investigators at Massachusetts General Hospital, Boston, in collaboration with the University of Antioquia, Medellin, Colombia, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, and Banner Alzheimer’s Institute, Phoenix, looked at genetic data from a Colombian family with more than 6,000 living members. Family members who carry a rare gene mutation called Presenilin 1 (PSEN1) E280A, have a 99.9% risk of developing early-onset Alzheimer’s disease.
The researchers confirmed that the woman in this case carried the PSEN1 E280A mutation, which caused early-onset Alzheimer’s in her other family members. However, she also had two copies of the APOE3ch gene variant, while no other affected family member carried two copies of this variant. Affected family members develop Alzheimer’s in their 40s, but she remained disease free until her 70s. Imaging tests showed that the woman had only minor neurodegeneration. She did have large amounts of amyloid protein deposits, a hallmark of Alzheimer’s disease, in her brain. But the amount of tau tangles, another hallmark of the disease, and the one more correlated with how thinking and memory are affected, was relatively low.
Experiments as part of the study showed that the APOE3ch variant may reduce the ability of APOE to bind to certain sugars called heparan sulphate proteoglycans (HSPG). APOE binding to HSPG has been implicated as one mechanism that may contribute to the amyloid and tau protein deposits that destroy the brain. The research suggests that a drug or gene therapy that could reduce APOE and HSPG binding has the potential to be a new way to treat or prevent Alzheimer’s disease.
Learn more: Unique case of disease resistance reveals possible Alzheimer’s treatment
The Latest on: Alzheimer’s
[google_news title=”” keyword=”Alzheimer’s” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Alzheimer’s
- Report: Alzheimer’s caregivers face significant health challenges as wellon March 23, 2023 at 10:54 pm
ROCHESTER — The Alzheimer’s Association 2023 Alzheimer’s Disease Facts and Figures report finds the burden on New York Alzheimer’s and dementia caregivers is growing. The new report, released March 15 ...
- Neuro Startup Cognito Corrals $73M as Alzheimer’s Device Commences Key Teston March 23, 2023 at 5:01 pm
Alzheimer’s disease research at MIT spawned Cognito Therapeutics, a startup whose medical device uses light and sound to modulate electrical activity that supports brain health. The company’s Series B ...
- Senators Press HHS Chief on Alzheimer's Drugs, Opioids at Budget Hearingon March 23, 2023 at 4:54 pm
Alzheimer's disease treatments, the opioid epidemic, and funding for rural healthcare were all in the spotlight during a Senate hearing on the Biden administration's ...
- Perivascular cells could induce microglial malfunction associated with Alzheimer's diseaseon March 23, 2023 at 7:23 am
Microglia are primary immune cells that safeguard the mammalian brain, partly by devouring or 'phagocytosing' pathogens and toxic debris. Recent genetic studies have consistently highlighted the role ...
- New bill bolsters importance of Alzheimer's awareness, early detectionon March 23, 2023 at 7:00 am
West Virginia Gov. Jim Justice signed Senate Bill 526 into law, which will increase education among health care professionals and members of the public regarding the importance of early detection ...
- Can light reset brainwaves to treat Alzheimer’s? This Boston startup has $73 million to find out.on March 22, 2023 at 1:16 pm
Cognito Therapeutics has started an advanced clinical study of its experimental device based on groundbreaking research at MIT.
- The Scary Link Between Our Molecular Clocks and Alzheimer’son March 22, 2023 at 10:58 am
Lukas BlazekWhen it comes to anti-aging science and research, there’s probably no topic more interesting than telomeres. There are caps at the end of chromosomes that act like the plastic bit at the ...
- Depression in Alzheimer's has different risk factors than depression in those without dementiaon March 22, 2023 at 10:19 am
Depression in Alzheimer's has different risk factors than depression in older adults without the disease, finds a major new study in the Journal of Alzheimer's Disease. The University of Bristol-led ...
- One step closer to Alzheimer's cure? Scientists find new genes that might helpon March 22, 2023 at 6:36 am
An international study has identified new genes that modulate the toxicity of the protein beta-amyloid, responsible for causing Alzheimer’s disease.
- Alzheimer’s Blood Test That Could Help Diagnose Disease Earlier Is Being Developed By Eli Lilly And Rocheon March 22, 2023 at 6:09 am
If approved, the test could streamline the diagnostic journey and help patients get earlier access to future Alzheimer’s treatments, Roche said.
via Bing News